Novartis AG (SWX: NOVN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 178.65B |
| Revenue (ttm) | 42.18B |
| Net Income (ttm) | 14.87B |
| Shares Out | 2.00B |
| EPS (ttm) | 7.25 |
| PE Ratio | 18.46 |
| Forward PE | 12.14 |
| Dividend | 3.30 (3.69%) |
| Ex-Dividend Date | n/a |
| Volume | 2,876,596 |
| Average Volume | 3,431,578 |
| Open | 89.15 |
| Previous Close | 89.23 |
| Day's Range | 89.15 - 89.78 |
| 52-Week Range | 83.63 - 102.72 |
| Beta | 0.51 |
| RSI | 45.18 |
| Earnings Date | Jan 31, 2025 |
About Novartis AG
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and ... [Read more]
Financial Performance
In 2023, Novartis AG's revenue was $46.66 billion, an increase of 7.36% compared to the previous year's $43.46 billion. Earnings were $14.85 billion, an increase of 113.52%.
Financial numbers in USD Financial StatementsNews
Pharmaceutical industry to work constructively with Trump, Novartis CEO says
Novartis CEO Vas Narasimhan says the pharmaceutical industry hopes to work constructively with the new Trump administration.
Appeals court lifts halt on generic Entresto launch: report
A U.S. appeals court has lifted a temporary halt it imposed the day before on the launch of a generic version of Novartis's (NVS) top-selling cardiac drug Entresto. Read more here.
US appeals court lifts pause on generic version of Novartis' Entresto
Drugmaker MSN Pharmaceuticals cleared another hurdle on Thursday toward launching its generic version of Novartis' blockbuster heart-failure drug Entresto after a U.S. appeals court ended a temporary ...
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
On Thursday, Outlook Therapeutics, Inc. (NASDAQ: OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular degene...
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
On Thursday, Outlook Therapeutics, Inc. OTLK completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular degeneration (wet...
Novartis loses emergency bid to block Entresto generic in US
A Washington, D.C. federal judge on Wednesday refused Novartis' eleventh-hour bid to block drugmaker MSN Pharmaceuticals from launching a generic version of Novartis' blockbuster heart-failure drug En...
Novartis AG (NVS) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
Novartis AG (NVS) JPMorgan 43rd Annual Healthcare Conference (Transcript)
Call Start: 12:00 Call End: 12:41 November 1, 0000 ETJPMorgan 43rd Annual Healthcare ConferenceJanuary 14, 2025 12:00 PM ETCompany ParticipantsVas...
Novartis CEO: We need to get Europe to pay its fair share
Novartis CEO Vas Narasimhan discusses the pricing of drugs in the U.S. compared to other countries.
Novartis CEO Vas Narasimhan: Expect solid growth this year top and bottom line
CNBC's Angelica Peebles and Novartis CEO Vas Narasimhan join 'Squawk Box' to discuss the company's drug pipeline, managing patent cliffs, drug pricing under Trump, and more.
Novartis CEO Vas Narasimhan: Expect solid growth this year top and bottom line
CNBCs Angelica Peebles and Novartis CEO Vas Narasimhan join 'Squawk Box' to discuss the company's drug pipeline, managing patent cliffs, drug pricing under Trump, and more.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
Novartis And BioAge Team Up To Develop Aging Therapies And Boost Investor Potential
Schrödinger receives regulatory approval for Novartis collaboration
Novartis Entresto® US patent upheld by US Court of Appeals
Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto® (sacubitril/valsartan) combination ...
Novartis: Explaining YE24 Loss Of Momentum, Outlining Prospects For 2025
AI, vaccine distrust, & the future of healthcare: Novartis CEO
Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan.
Light Horse Therapeutics Enters Into Strategic Collaboration With Novartis
Discovery collaboration provides a $25 million upfront payment and up to $1 billion in research, development and sales milestone payments SAN DIEGO — Light Horse Therapeutics Inc., a developer of firs...
Light Horse Therapeutics Enters Into Strategic Collaboration With Novartis
SAN DIEGO--(BUSINESS WIRE)--Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, announced a multi-target collaboration with Novartis to identify and develop poten...
Novartis gene therapy helps children with rare muscle disorder in study
Swiss drugmaker Novartis said on Monday its gene therapy helped improve motor function in children with a rare muscle disorder that leaves patients too weak to walk, talk and swallow.
Novartis reports positive results for intrathecal Zolgensma
Novartis (NVS) Reports Positive Trial Results for New SMA Drug
Novartis (NVS) Reports Positive Trial Results for New SMA Drug
Novartis Says New Drug Helps Children With Rare Spinal Condition
Novartis AG said a new experimental medicine improved motor function in children with a form of spinal muscular atrophy, the devastating disorder targeted by its gene therapy Zolgensma, in an advanced...
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onase...
Novartis to face whistleblower case on MS drug kickbacks: report
A U.S. court of appeals has reportedly ruled that a whistleblower case against Novartis (NVS) over alleged kickbacks involving its multiple sclerosis drug Gilenya can proceed.